Document is current
Any future updates will be listed below
-
Authors
Miwa, Takao https://orcid.org/0000-0002-6373-260X
Tsuruoka, Mio
Ueda, Hajime
Abe, Tamami
Inada, Hiroki
Yukawa-Muto, Yoshimi
Ohara, Masatsugu
Arai, Taeang
Tamai, Yasuyuki
Isoda, Hiroshi
Tadokoro, Tomoko
Hanai, Tatsunori
Ito, Takanori
Tamaki, Nobuharu
Sakamaki, Akira
Aoki, Yoshihiko
Tada, Fujimasa
Yoshio, Sachiyo
Takahashi, Hirokazu
Morishita, Asahiro
Ishikawa, Tsuyoshi
Inoue, Jun
Suda, Goki
Ogawa, Chikara
Atsukawa, Masanori
Hiraoka, Atsushi
Kuroda, Hidekatsu
Namisaki, Tadashi
Honda, Takashi
Kawaguchi, Takumi
Tanaka, Yasuhito
Terai, Shuji
Ikegami, Tadashi
Yoshiji, Hitoshi
Iwasa, Motoh
Shimizu, Masahito
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP24K18908)
Japan Agency for Medical Research and Development (24fk0210154)
Gifu University
- License Information
-
More Information
Article History
Received: 14 January 2025
Accepted: 16 February 2025
First Online: 7 March 2025
Declarations
:
: Takanori Ito received lecture fees from AstraZeneca PLC. And Chugai Pharmaceutical Co., Ltd., and research funding from Chugai Pharmaceutical Co., Ltd., outside the submitted work. Takumi Kawaguchi received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK, Eisai Co., Ltd., Novo Nordisk Pharma Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd. Hirokazu Takahashi received lecture fees from Novo Nordisk Pharma Ltd., Kowa Company, Ltd., and Taisho Pharmaceutical Co., Ltd. Hirokazu Takahashi also received research grants from Takeda Pharmaceutical Co., Ltd. and Sysmex Co., Ltd. Yasuhito Tanaka received lecture fees from AbbVie GK, Eisai Co., Gilead Sciences Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., GlaxoSmithKline PLC., AstraZeneca PLC., Eisai Co., Ltd., and H.U. Frontier Co., Ltd. Yasuhito Tanaka also received research grants from AbbVie GK, Janssen Pharmaceutical K.K., Fujirebio Co., Ltd., GlaxoSmithKline PLC., Sysmex Co., Ltd., and Gilead Sciences Co., Ltd. Yasuhito Tanaka also received scholarship grants from AbbVie GK and Otsuka Pharmaceutical Co., Ltd. Shuji Terai received lecture fees from Otsuka Pharmaceutical Co., Ltd., AbbVie GK, ASKA Pharmaceutical Co., Ltd., Chiome Bioscience Inc., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K. Shuji Terai also received research grants from Rohto Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Fuji Pharma Co.,Ltd., StemRIM Inc., Abbott Japan LLC, Kowa Company, Ltd., Shionogi & Co., Ltd., Cuorips Inc., and Japan Bio Products Co., Ltd. Shuji Terai also received scholarship grants from Otsuka Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., AbbVie GK, Sumitomo Pharma Co., Ltd., and Asahi Kasei Pharma Corporation Co., Ltd. Hitoshi Yoshiji received lecture fees from Otsuka Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Gilead Sciences Co., Ltd., Nobelpharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and AbbVie GK. Other authors declare that they have no conflict of interest.
